Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Roivant Sciences Ltd.

ROIVNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 18, 2026Accepted Nov 18, 2026, 6:08 PM ESTFiling CIK 1635088Accession 0001193125-26-467345
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-11-16
Issuer
Roivant Sciences Ltd.
Issuer CIK
0001635088
Trading symbol
ROIV

Reporting owner 1

Name
MANCHESTER KEITH S
Reporting owner CIK
0001244828
Relationship
Director
Address
C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM, UNITED KINGDOM, X0, SW1H 0DB

Non-derivative transactions

Non-derivative transactions · 10 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Shares2026-11-16S · Form 479,461D39.1713,609,705I[F1]Held by QVT Financial Investment Cayman Ltd.
Common Shares2026-11-16S · Form 4550,280D39.171,042,200I[F1]Held by QVT P&E Roiv Hldgs Ltd
Common Shares2026-11-16S · Form 418,927D38.9913,590,778I[F1]Held by QVT Financial Investment Cayman Ltd.
Common Shares2026-11-16S · Form 4131,073D38.99911,127I[F1]Held by QVT P&E Roiv Hldgs Ltd
Common Shares2026-11-17J · Form 4[F2]2,635,169D0.005,806,259I[F1]Held by QVT Deferred Compensation Holdings Ltd.
Common Shares2026-11-17J · Form 4[F2]15,969D0.0013,574,809I[F1]Held by QVT Financial Investment Cayman Ltd.
Common Shares2026-11-17J · Form 4[F2]385,620D0.00525,507I[F1]Held by QVT P&E Roiv Hldgs Ltd
Common Shares2026-11-17S · Form 475,716D38.2413,499,093I[F1]Held by QVT Financial Investment Cayman Ltd.
Common Shares2026-11-17S · Form 4525,507D38.240I[F1]Held by QVT P&E Roiv Hldgs Ltd
Common Shares2026-11-17S · Form 4798D38.245,805,461I[F1]Held by QVT Deferred Compensation Holdings Ltd.
Table key
S · Form 4
Sale on the market or privately
D
Disposed
I
Indirect
J · Form 4
Other acquisition or disposition; see explanation

Footnotes

F1
The reporting person is a shareholder of each of QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
F2
On November 17, 2026, each of the QVT Entities made an in-kind distribution on a pro rata basis, for no consideration.↩ 1↩ 2↩ 3

Signature 1

Signed
/s/ Keith Manchester
Date
2026-11-18

Company context

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Current securities

Historical securities (3)

Recent company filings

  1. 4 filingNov 18, 2026
  2. 10-Q filingNov 9, 2026
  3. Results of Operations and Financial ConditionNov 9, 2026
  4. SCHEDULE 13G/A - filed by FMR LLC regarding Roivant Sciences Ltd.Nov 5, 2026
  5. 4 filingOct 27, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.